fbpx Skip to main content

WEDNESDAY, March 3, 2021 (HealthDay News) — Discordance between patient and physician assessments of psoriasis severity is associated with patient depression and anxiety, according to a study published online March 3 in JAMA Dermatology.

Ewan Carr, Ph.D., from King’s College London, and colleagues conducted a cohort study to examine discordance between patient- and physician-reported measures of psoriasis severity and examine the correlation with patient mental health status. Data were included for 502 patients between May 12, 2016, and Nov. 1, 2018, with 1,985 total observations.

Of the patients, 9 and 10 percent, respectively, screened positive for depression and anxiety. The researchers found that in 39 percent of the observations, there was discordance between physician and patient measures of disease severity; in 26 and 13 percent of visits, patients rated their psoriasis as less and more severe, respectively, compared with their physicians. The likelihood of a patient overestimating their psoriasis severity compared with their physician was increased for those who screened positive for depression or anxiety (relative risk ratios, 2.7 and 2.1 for depression and anxiety, respectively). After adjustment for age, ethnicity, sex, and other confounding variables, these findings remained statistically significant.

“The recognition, monitoring, and management of depression and anxiety in psoriasis by multidisciplinary health care teams (preferably encompassing clinical psychology expertise) has the potential to alleviate the substantial mental health burden in psoriasis while aligning clinician and patient perceptions of disease and treatment goals,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  How Racism Impacts Asthma and Atopic Dermatitis

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More